However, clinical implications of germline and somatic HRR gene alterations, besides germline BRCA2 mutations, in prostate cancer remain uncertain due to limited studies, number of patients enrolled, and available approved treatments [13]. The gene discussed is BRCA2; the disease is prostate carcinoma.